This report from SAMHSA provides an updated overview of three Food and Drug Administration-approved medications for opioid use disorder treatment—methadone, naltrexone, and buprenorphine—and other strategies and services needed to support people in treatment. It is targeted towards healthcare and addiction professionals, policymakers, patients, and their families.